Good MorningEquity markets rebounded on Thursday, erasing some but not all of Wednesday's losses. The move in the S&P 500 was largely driven by tech, led by a 20% gain in Tesla. Tesla reported a mixed quarter with a wider-than-expected margin; the news sending shares higher was the outlook for robust production and delivery growth in 2025. CEO Elon Musk estimates the growth at something like 20% to 30%, driven by a yet-to-be-seen lower-priced model.
The risk for the market next week is enormous, including earnings and economic data. The earnings deluge will continue with over 100 reports from S&P 500 Companies, including key reads from big tech names like Microsoft and Amazon. On the economic front, reports on third-quarter GDP, the PCE price index, and labor markets will drive the action. The risk is that weaker-than-expected data will raise the fear of a recession. Hot data is good news any way you look at it. The Fed may back off on the pace of interest rate cuts because of hot data, but economic and earnings growth will offset it and continue to drive stocks higher. Featured: The real story behind China's 'seizure' of US farmland (Colonial Metals) 
|
Markets | | |
Transportation stocks typically indicate the economy's current state, while airline stocks gauge the consumer cycle's direction instead. Recently, shares of Spirit Airlines Inc. (NYSE: SAVE) have nearly doubled after the company struck a new deal to help keep its debt burden flexible ahead of bond... Read the Full Story |
|
From Our PartnersKamala Harris is the official Democratic nominee, and with her comes a new era of economic policy. Is your portfolio prepared for the potential market shakeup? Discover the assets you need to protect your investments in uncertain times.
By following the link above or using any of the links provided below, you're choosing to opt in to receive insightful updates from Wealth Creation Investing + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details. | | | | Download the Free Guide Now |
|
Markets | | |
Meta Platforms Inc (NASDAQ: META) has been having a good year. Its ongoing rally, which kicked off around this time in 2022, is continuing to go from strength to strength and analysts are calling for even more gains ahead in the coming weeks.
With an eye-watering market cap of $1.4 trillion, th... Read the Full Story |
|
Markets | | |
Lucid Group, Inc. (NASDAQ: LCID) has made headlines with its recent stock sale, raising a staggering $1.75 billion. CEO Peter Rawlinson has confidently declared that this will fuel the company’s operations "well into 2026," allowing them to ramp up production of the Gravity SUV and launch ne... Read the Full Story |
|
From Our PartnersIf you missed it, my emergency election broadcast is now available - but will be removed soon | | | | Click here to watch it now. |
|
Stocks | | | U.S. stock indexes gave up an early gain and drifted to a mixed finish Friday, helping give the market its first losing week since early September.The S&P 500 closed little changed after having been up 0.9% earlier in the day. The benchmark index ended the week 1% lower, ending a six-week winnin... Read the Full Story |
|
Markets | | |
Space stocks have had plenty of reasons to soar this fall. Non-public Elon Musk venture SpaceX completed a significant flight test of its Starship in October, while NASA's Europa Clipper departed for Jupiter's moon. Meanwhile, AST SpaceMobile Inc. (NASDAQ: ASTS) has skyrocketed by nearly 800% in t... Read the Full Story |
|
From Our PartnersEarlier this year President Biden signed the death warrant for America…
Executive Order 14067 will essentially cancel your money.
You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar... | | | | Get your free information kit NOW, before it's too late. |
|
Markets | | |
Tesla (NASDAQ: TSLA) is a good company, but that doesn’t mean its stock price will have a significant rally anytime soon. The market for Tesla is valued in many different ways for many reasons, including its status as a vehicle OEM, an EV pure-play, a tech innovator, its energy business, AI,... Read the Full Story |
|
Markets | | | The average rate on a 30-year mortgage in the U.S. rose again this week, reaching its highest level in nearly three months. The rate rose to 6.54% from 6.44% last week, mortgage buyer Freddie Mac said Thursday. Despite the recent uptick, the average rate is down from a year ago, when it climbed to a... Read the Full Story |
|
Markets | | | The world economy, buffeted by conflict and growing geopolitical rivalries, is in danger of getting stuck in a slow-growth, high-debt rut, the head of the International Monetary Fund warned Thursday. She also urged Chinese leaders to take more decisive action to jump-start their country's sluggish e... Read the Full Story |
|
Markets | | | Russia’s central bank on Friday raised its key interest rate by two percentage points to a record-high 21% in an effort to stem growing inflation as massive government spending on the military amid the fighting in Ukraine strains the economy’s capacity to produce goods and services and drives up wor... Read the Full Story |
|
Markets | | | When labor disputes disrupted operations at Canada's two largest railroads and ports up and down the East Coast, many companies shifted more of their shipments to the West Coast forcing railroads like Union Pacific and the ports there to react quickly.Union Pacific said Thursday that the result was ... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
